News for Knight Therapeutics Inc. (KHTRF)

WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceutic

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Gl…

FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGT

**media[579350]**

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced to…

Knight Therapeutics Inc (TSX:GUD) is set to release its Q4 2024 earnings on Mar 20, 2025. The consensus estimate for Q4 2024 revenue is $86.18 million, and the

Revenue: Over $365 million for 2024, a 6% increase from the previous year.Adjusted EBITDA: Approximately $58 million for 2024, a decrease of 4% compared to las

Mar 20, 2025 / 12:30PM GMTOperator Good morning, ladies and gentlemen. My name is Sylvie, and I will be your conference operator today. Welcome to Knight Therap

Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ETCompany ParticipantsSamira Sakhia - President and Chief...

PR NewswireMALVERN, Pa., March 11, 2025 MALVERN, Pa., March 11, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it

**media[562977]**

**media[538058]**

Raised approximately $2.118 million in gross proceeds since the beginning of 2025 WASHINGTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals,

**media[534489]**

**media[528476]**

**media[527224]**

MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutica…

WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. ( SXTP; SXTPW) (”œ60 Degrees” or the ”œCompany”), pharmaceutical company,

**media[493965]**